The short-acting insulin market is estimated to be valued at USD 9.5 Bn in 2024 and is expected to reach USD 13.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031. https://logcla.com/blogs/467718/The-Short-Acting-Insulin-Market-is-Anticipated-to-Witness-Steady